High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306595 ↗Kurz gefasst
Klinische Studie in der Zeitschrift PLOS ONE, 2024. Verfasst von Xiyue Yang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Mianyang Central Hospital, Mianyang, China. Hauptthemen laut MEDLINE: Liver Neoplasms, High-Intensity Focused Ultrasound Ablation, Immunotherapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Ultrasound in Medicine and Engineering.
Abstract (Originalsprache)
Purpose
Given the unique features of the liver, it is necessary to combine immunotherapy with other therapies to improve its efficacy in patients of advanced cancer with liver metastases (LM). High-intensity focused ultrasound (HIFU) ablation is now widely used in clinical practice and can enhanced immune benefits. The study is intended to prospectively evaluate the safety and clinical feasibility of HIFU ablation in combination with systemic immunotherapy for patients with liver metastases.
Methods
The study enrolled 14 patients with LM who received ultrasound-guided HIFU ablation combined with immune checkpoint inhibitors (ICIs) such as anti-programmed cell death protein 1 (anti-PD-1 agents manufactured in China) at Mianyang Central Hospital. Patients were followed up for adverse events (AEs) during the trial, using the CommonTerminology Criteria for Adverse Events v5.0(CTCAE v5.0) as the standard. Tumour response after treatment was assessed using computerized tomography.
Results
The 14 patients (age range, 35–84 years) underwent HIFU ablation at 19 metastatic sites and systemic immunotherapy. The mean lesion volume was 179.9 cm3 (maximum: 733.1 cm3). Median follow-up for this trial was 9 months (range: 3–21) months. The study is clinically feasible and acceptable to patients.
Conclusion
This prospective study confirmed that HIFU combined with immunotherapy is clinically feasible and safe for treating liver metastases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Mianyang Central Hospital, Mianyang, China.
- State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
- Sichuan Clinical Research Center for Radiation and Therapy, Mianyang, China.
- Chongqing Key Laboratory of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
ORCID-Profile: Xiaobo Du
Förderung
- State Key Laboratory of Ultrasound in Medicine and Engineering
Zitieren
APA
Yang, X., Liao, Y., Fan, L., Lin, B., Li, J., Wu, D., Liao, D., Yuan, L., Liu, J., Gao, F., Feng, G., & Du, X. (2024). High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0306595
Vancouver
Yang X, Liao Y, Fan L, Lin B, Li J, Wu D, et al. High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial. PLOS ONE. 2024. doi:10.1371/journal.pone.0306595
BibTeX
@article{Yang2024,
author = {Yang, Xiyue and Liao, Yao and Fan, Lingli and Lin, Binwei and Li, Jie and Wu, Danfeng and Liao, Dongbiao and Yuan, Li and Liu, Jihui and Gao, Feng and Feng, Gang and Du, Xiaobo},
title = {High-intensity focused ultrasound ablation combined with immunotherapy for treating liver metastases: A prospective non-randomized trial},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306595}
}
EUVIMED